BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26577244)

  • 1. Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.
    Tsujioka T; Yokoi A; Itano Y; Takahashi K; Ouchida M; Okamoto S; Kondo T; Suemori S; Tohyama Y; Tohyama K
    Sci Rep; 2015 Nov; 5():16709. PubMed ID: 26577244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines.
    Tsujioka T; Yokoi A; Uesugi M; Kishimoto M; Tochigi A; Suemori S; Tohyama Y; Tohyama K
    Exp Hematol; 2013 Feb; 41(2):189-97. PubMed ID: 23085465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
    Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
    Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
    Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
    Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
    Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
    Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
    Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
    Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
    Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
    Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
    Link PA; Baer MR; James SR; Jones DA; Karpf AR
    Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
    Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
    Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic therapy with decitabine for myelodysplasia and leukemia.
    Wijermans P; Lübert M
    Future Oncol; 2005 Oct; 1(5):585-91. PubMed ID: 16556035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
    Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.
    Giachelia M; D'Alò F; Fabiani E; Saulnier N; Di Ruscio A; Guidi F; Hohaus S; Voso MT; Leone G
    Leuk Res; 2011 Apr; 35(4):465-71. PubMed ID: 20869114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation.
    Grövdal M; Karimi M; Tobiasson M; Reinius L; Jansson M; Ekwall K; Ungerstedt J; Kere J; Greco D; Hellström-Lindberg E
    Leukemia; 2014 Feb; 28(2):411-3. PubMed ID: 24025691
    [No Abstract]   [Full Text] [Related]  

  • 18. Epigenetic control of NF-κB-dependent FAS gene transcription during progression of myelodysplastic syndromes.
    Ettou S; Humbrecht C; Benet B; Billot K; d'Allard D; Mariot V; Goodhardt M; Kosmider O; Mayeux P; Solary E; Fontenay M
    Mol Cancer Res; 2013 Jul; 11(7):724-35. PubMed ID: 23604035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methyltransferases as targets for cancer therapy.
    Ghoshal K; Bai S
    Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.